In:
Journal of Hepato-Biliary-Pancreatic Sciences, Wiley, Vol. 27, No. 10 ( 2020-10), p. 682-689
Abstract:
This study aimed to evaluate the prognostic impact of the 5‐5‐500 rule in patients after hepatic resection for the intermediate stage of hepatocellular carcinoma (HCC; The Barcelona Clinic Liver Cancer classification [BCLC] B). Methods 177 patients had hepatic resection for BCLC‐B HCC. The 5‐5‐500 rule was defined by tumor size ≤5 cm in diameter, tumor number ≤5, and α‐fetoprotein ≤500 ng/mL. Results The 3‐, 5‐, and 7‐year recurrence‐free survival rates were 22%, 14%, and 11% in patients within the 5‐5‐500 rule, and 16%, 10%, and 10% in patients beyond the 5‐5‐500 rule, respectively ( P = .015). The 3‐, 5‐, and 7‐year overall survival rates were 72%, 47%, and 34% in patients within the 5‐5‐500 rule, and 52%, 31%, and 25% in patients beyond the 5‐5‐500 rule, respectively ( P = .035). Being beyond the 5‐5‐500 rule and liver cirrhosis were independent prognostic factors for recurrence‐free survival. For overall survival, being beyond the 5‐5‐500 rule, age ≥65 years, Child–Pugh class B, and anti‐hepatitis C antibody positive were identified as independent prognostic factors. Conclusions The 5‐5‐500 rule could predict prognosis in BCLC‐B patients with hepatic resection. Hepatic resection might provide survival benefit for selected patients with BCLC‐B HCC within the 5‐5‐500 rule.
Type of Medium:
Online Resource
ISSN:
1868-6974
,
1868-6982
Language:
English
Publisher:
Wiley
Publication Date:
2020
detail.hit.zdb_id:
2536390-6